ArticleFrontiers in immunology2025
Correlation between increased total serum IgE levels and clinical features in alopecia areata patients.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunopathogenesis and Experimental Models of Alopecia Areata: From Mechanistic Insights to Translational Platforms.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Alopecia areata (AA) is primarily associated with a Type 1 (Th1) inflammatory response, but emerging evidence also suggests a potential contribution of Type 2 (Th2) immunity. However, the relationship between IgE levels and pathogenesis of AA, as well as its clinical features, remains unclear, with limited and conflicting evidence in current research. This study aims to compare the total serum IgE levels between AA patients without atopic diseases and healthy controls, and to examine the correlation of IgE levels with gender, age, disease severity, disease duration, and affection of eyebrows, eyelashes, and nails. Methods: AA patients without other hair loss diseases and conditions, or systemic treatment known to affect serum IgE were included. Medical records of 436 patients and 181 normal controls were retrospectively analyzed between May 2018 and November 2024. Among AA patients, clinical features and total serum IgE levels were analyzed. Results: The elevated total serum IgE rate was observed in 31.0% of AA patients, which was significantly higher than that in control groups (P < 0.001). Among AA patients, total serum IgE levels differed significantly by gender (P = 0.002), age (P < 0.001), and disease severity (P = 0.040). Patients with alopecia universalis or totalis (AU/AT) had higher total serum IgE levels compared to those with localized AA (P = 0.049). No significant correlation was found between total serum IgE levels and disease duration. Conclusions: Our research reveal that total serum IgE levels are elevated in AA patients compared to control group. Male patients, children, and individuals with moderate-severe AA patients showed significantly higher IgE levels. These results suggest the involvement of IgE and Th2 cytokines in AA pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.